再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

未开盘 09-10 16:08:44

18.770

-1.230

-6.15%

最高19.990	最低18.630	成交量1,001万
今开19.990	昨收20.000	日振幅6.80%
总市值213.60亿	流通市值213.60亿	总股本11.38亿
成交额1.90亿	换手率0.88%	流通股本11.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":18.77,"timestamp":1789027724003,"preClose":20,"halted":0,"volume":10011700,"delay":0,"changeRate":-0.06150000000000002,"floatShares":1138000000,"shares":1138000000,"eps":-1.256680885766263,"marketStatus":"未开盘","change":-1.23,"latestTime":"09-10 16:08:44","open":19.99,"high":19.99,"low":18.63,"amount":189976558,"amplitude":0.068,"askPrice":18.77,"askSize":4500,"bidPrice":18.76,"bidSize":10300,"shortable":3,"etf":0,"ttmEps":-1.335353804654664,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":20,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":2.0012239574874275,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688","defaultTab":"news","newsList":[{"id":"2666998175","title":"纳斯达克中国金龙指数跌超0.5%，再鼎医药跌5.03%，金山云跌4.26%，禾赛科技跌3.17%，晶科能源跌3.04%，","url":"https://stock-news.laohu8.com/highlight/detail?id=2666998175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666998175?lang=zh_cn&edition=full","pubTime":"2026-09-10 21:30","pubTimestamp":1789047045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4548","02525","BK4139","BK4563","BK4124","LU2476274720.SGD","09688","BK4585","ZLAB","BK4588","ACES","BK4526","BK4141","BK4531","BK4607","BK4608","LU2778985437.USD","JKS","LU2476274308.USD","BK4519","BK4116","HSAI","KC","LU2488822045.USD","03896","HXC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151193334","title":"异动解读｜再鼎医药盘中下跌5.1%，中报亏损扩大叠加生物科技板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1151193334","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151193334?lang=zh_cn&edition=full","pubTime":"2026-09-10 14:00","pubTimestamp":1789020003,"startTime":"0","endTime":"0","summary":"9月10日，再鼎医药盘中下跌5.1%，报18.98港元，成交额9144.57万港元。消息面上，公司此前披露上半年业绩，总收入2.06亿美元，同比下降5%；净亏损1.02亿美元，同比扩大14%。研发开支增加14%至1.27亿美元，进一步拖累利润表现。此外，当日生物科技板块整体承压，云顶新耀跌8.2%、三生制药跌3.65%、信达生物跌3.26%，板块联动加剧个股调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"再鼎医药走低，中报亏损扩大拖累股价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","LU2580892862.HKD","BK1141","LU2148510915.USD","09926","LU0463099449.HKD","LU1813983027.USD","LU0181495838.USD","LU0516422952.EUR","SG9999004220.SGD","LU0979878070.USD","LU0572944931.SGD","KURE","01801","09995","LU0417516738.SGD","06160","LU1580142542.USD","LU1226287875.USD","LU1794554557.SGD","01093","LU1880383366.USD","LU0348825331.USD","LU2039709279.SGD","06030","06185","LU1226287792.SGD","LU1969619763.USD","02142","02616","BK0028","LU0561508036.HKD","LU1820825898.SGD","LU0405327494.USD","LU1255011170.USD","02269","01177","600030","LU1961090484.USD","LU0819121731.USD","IE0008369823.USD","KCE","01877","LU1064130708.USD","LU1655091616.SGD","09688","LU1997245177.USD","LU0348783233.USD","BK1161","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398249","title":"【券商聚焦】中信建投：上半年收入与利润双增，医药行业步入新发展周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398249","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398249?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:04","pubTimestamp":1788743053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业整体收入与扣非净利润实现双增长，创新药、CXO、制药装备及科学试剂等板块积极复苏，行业步入新发展周期。创新药收入+58.68%，扭亏为盈，出海总金额超900亿美元，全年有望超越2025年水平，国际化持续兑现；CXO收入+25.2%，扣非净利润+66.5%，订单旺盛，上行周期确立。随着集采出清、创新放量、出海落地及上游国产化提升，行业有望开启高质量发展周期，龙头将持续受益。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1191","BK1500","LU2476274308.USD","LU2399975544.HKD","BK1583","09926","KCE","LU0348825331.USD","IE00BPRC5H50.USD","BK1161","LU1115378108.SGD","BK1515","KURE","LU2476274720.SGD","09688","02268","IE00B3M56506.USD","LU0588546209.SGD","03933","BK1593","06160","LU0348827113.USD","BK1585","01099","01530","BK1588","LU0828237510.HKD","LU1969619763.USD","LU0417516902.SGD","BK1197","BK1574","02228","LU0640798160.USD","BK1141","01789","LU2328871848.SGD","SG9999004311.SGD","LU2488822045.USD","LU1770034418.SGD","02367","02196","601066","BK1207","HK0000165453.HKD","06821","LU0228659784.USD","LU1720050803.USD","IE00B5MMRT66.SGD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182558980","title":"再鼎医药更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1182558980","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182558980?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:46","pubTimestamp":1788515180,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司于2026年9月4日披露了截至2026年8月31日的证券变动月报表。在已发行股份及库存股方面，公司上月底及本月底的已发行普通股股数均为1,137,828,030股，库存股数为0股，表明2026年8月期间未发生新的股份发行、回购或注销，整体股本规模维持不变。公司在公告中亦确认截至2026年8月末已达到或符合适用的公众持股量要求。鉴于本期无新增股份发行与回购活动，公司股本结构保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664122038","title":"美股异动 | 再鼎医药涨逾7%，DLL3 ADC启动一线SCLC全球三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664122038","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664122038?lang=zh_cn&edition=full","pubTime":"2026-09-02 21:58","pubTimestamp":1788357538,"startTime":"0","endTime":"0","summary":"消息面上，8月31日，$再鼎医药$在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者，预计2030年6月初步完成。ZL-1310为一款靶向DLL3的ADC新药，采用宜联新一代ADC技术TMALIN构建，以TOPO1抑制剂作为payload，具有高效力、高清除率和高渗透性的作用特点。ZL-1310在小细胞肺癌PDX模型的临床前研究中显示出强效杀伤作用。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491227.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药DLL3 ADC启动一线SCLC全球三期临床","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4548","BK1588","BK4526","09688","BK4531","BK1574","BK4588","ZLAB","LU2488822045.USD","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664898546","title":"再鼎医药早盘涨逾6% DLL3 ADC启动一线SCLC全球三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664898546","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664898546?lang=zh_cn&edition=full","pubTime":"2026-09-02 10:16","pubTimestamp":1788315360,"startTime":"0","endTime":"0","summary":"模拟交易客户端再鼎医药早盘涨逾6%。截至发稿，股价上涨5.97%，现报20.60港元，成交额5967.91万港元。8月31日，再鼎医药在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者，预计2030年6月初步完成。2026 年下半年重要催化剂包括：Zoci一线小细胞肺癌联合治疗数据公布、1L SCLC 及肺外神经内分泌癌注册性开发推进；ZL-1503首次人体数据公布等。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-02/doc-iniqkzme7832199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4531","BK4588","BK1161","09688","BK4526","BK1588","LU2488822045.USD","ZLAB","BK4548","BK1574","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171094616","title":"异动解读｜再鼎医药盘中上涨5.86%，知名机构大手笔增持提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1171094616","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171094616?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:55","pubTimestamp":1788314128,"startTime":"0","endTime":"0","summary":"9月2日，再鼎医药盘中上涨5.86%，报20.58港元，成交额3169.58万港元。此前公司中期业绩公布后股价一度承压，近期出现明显反弹。消息面上，知名医药投资机构RTW Investments于8月20日以每股均价26美元大举增持约1230.72万股，涉资约3.20亿美元，持股比例由7.17%升至8.25%，显示机构对公司长期价值的认可。合作伙伴argenx核心产品FcRn拮抗剂治疗自身免疫性肌炎的三期临床取得积极结果，再鼎拥有大中华区权益，有望进一步拓展商业化版图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药异动上涨，机构增持释放积极信号","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664186027","title":"港股异动 | 再鼎医药(09688.HK)早盘涨近5% DLL3 ADC启动一线SCLC全球三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664186027","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664186027?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:44","pubTimestamp":1788313443,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","LU2488822045.USD","09688","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663049960","title":"再鼎医药（ZLAB）盘中震荡走软跌4.43% 中期归属于上市公司股东净亏损同比扩大14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663049960","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663049960?lang=zh_cn&edition=full","pubTime":"2026-08-31 23:02","pubTimestamp":1788188527,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药（ZLAB）盘中震荡走软，截至发稿，最新报24.93美元，下跌4.43%，成交额621.24万美元。消息面上，再鼎医药新近披露2026年中期财报，年初至报告期末实现营业收入2.06亿美元，同比下降5%；归属于上市公司股东的净亏损为1.02亿美元，同比扩大14%。截至2026年6月30日，公司资产合计10.75亿美元，负债合计4.68亿美元，基本及摊薄每股亏损为0.09美元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/N2NlYWIzMDQ5MjY5YzU0NWM0NDMwZTE4ZDQ3MjY3ODIxNTA5MDg=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305520","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","BK4526","BK1588","BK4531","BK4548","BK4585","BK1574","BK4588","ZLAB","09688","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663988006","title":"纳斯达克中国金龙指数跌超0.5%，乐信跌13.14%，小马智行跌4.75%，贝壳跌2.70%，再鼎医药跌2.03%，阿里","url":"https://stock-news.laohu8.com/highlight/detail?id=2663988006","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663988006?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:30","pubTimestamp":1788183025,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1046422090.SGD","LU0661504455.SGD","LU0463099449.HKD","BABO","LU1008478684.HKD","LU1152091168.USD","IE00BF5LJ272.USD","BK4502","BK4535","BK4548","LU0359201612.USD","LU0797268264.HKD","BK4585","LU1051768304.USD","LU1188198961.HKD","LU0287142896.SGD","BK4558","LU0359202008.SGD","LU2488822045.USD","LU0553294199.USD","LU1046421795.USD","LU1242518931.SGD","KBAB","LU0047713382.USD","LU0052756011.USD","LU0359201885.HKD","LU0651947912.USD","BK4509","PONY","LU0738911758.USD","LU1282648689.USD","BK4122","LU1235294995.USD","LU1048588211.SGD","BK4524","HXC","BK4565","LU0072913022.USD","BK4534","BK4079","BK4526","LU1051769294.HKD","BK4503","LU0106959298.USD","LU0328353924.USD","ALBmain","BK4554","BK4527","LU0251143458.SGD","LX","BK4614","BK4587","LU0348816934.USD","LU0310800965.SGD","BABA","LU0949170772.SGD","BEKE","BK4607","LU0348814723.USD","02423","LU1105468828.SGD","LU0651946864.USD","BK4166","BK4023","LU1003077747.HKD","CLIX","LU0326950275.SGD","BK4538","BK4531","DRAG","09988","BABX","LU1688375341.USD","LU1152091754.HKD","BABC","LU0918141705.HKD","ZLAB","LU1515016050.SGD","BK4588","LU1823568750.SGD","PONX","LU0501845795.SGD","BBYY","LU0067412154.USD","LU1769817179.HKD","LU0173614495.USD","BK4139","LU1267930227.SGD","LU0049112450.USD","LU0821914370.USD","LU0244354667.USD","IE00B0JY6N72.USD","LU1242518857.USD","LU1831875114.USD","BK4533","LU0128525689.USD","BK4220","LU1235295612.USD","BK4575","LU1048596156.SGD","IE00BFMHRM44.USD","LU0918141887.USD","LU0545039389.USD","02026","BK4579","LU0072462343.USD","LU2226246903.HKD","BK4504","BK4505","LU1769817096.USD","LU1023057109.AUD","BK4581","LU0880133367.SGD","LU0979878070.USD","LU2148611432.USD","BABU","LU0456842615.SGD","09688","BK4543","BABW","LU1880383366.USD","ONLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141343244","title":"异动解读｜再鼎医药盘中上涨5.17%，中期业绩发布叠加机构大举增持提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1141343244","media":"行情直击","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141343244?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:57","pubTimestamp":1787817479,"startTime":"0","endTime":"0","summary":"8月27日，再鼎医药盘中上涨5.17%，报21.14港元，成交额1.78亿港元。消息面上，公司于8月26日发布中期业绩，上半年总收入2.06亿美元，产品收入净额2.01亿美元，同比下降6%，主因则乐受仿制药集采冲击及卫伟迦医保续约降价，但鼎优乐及纽再乐销售增长形成部分对冲。净亏损1.02亿美元，同比扩大14%，主因许可费增加推升研发开支至1.27亿美元。此外，RTW Investments于8月20日斥资约3.20亿美元增持公司股份，持股比例升至8.25%，显示机构对公司长期价值的认可。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药盘中上涨，机构大举增持提振信心","news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729977","title":"【券商聚焦】国投证券：创新药有望开启新一轮高景气周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729977","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662729977?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:29","pubTimestamp":1787794154,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券研究指，医药景气新周期背景下，国内创新药产业链加速崛起。近年国家多举措全链条支持创新药发展，叠加国内得天独厚的人才储备和研发效率等多维优势，国内创新药持续加速崛起且逐步具备全球竞争力。与此同时，海外MNC陆续面临专利悬崖困境，对外采购和扩充创新管线需求与日俱增，国内创新药企顺势而为，以海外授权BD等形式实现创新出海，创新药有望开启新一轮高景气周期。风险提示：产品研发及审批速度低于预期；产品降价超预期风险；海外BD授权不及预期风险；计算及假设不及预期风险。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989630","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","LU0634319403.HKD","SG9999002562.SGD","09688","IE00BPRC5H50.USD","LU1794554557.SGD","01093","LU1770034418.SGD","01177","LU2242644610.SGD","LU1969619763.USD","LU0307460666.USD","02142","KCE","01877","LU0516422952.EUR","KURE","LU0348767384.USD","06160","06978","LU0314109678.HKD","IBBQ","LU0051755006.USD","02616","IE0008369823.USD","159992","01801","LU0359201612.USD","LU0348825331.USD","06185","LU0039217434.USD","161027","BK1589","LU0516423091.SGD","LU0348783233.USD","LU0880133367.SGD","MEDX","09926","02269","LU0417516738.SGD","LU0463099449.HKD","SG9999004220.SGD","LU1807302812.USD","LU1813983027.USD","LNGR","LU0326950275.SGD","LU0455707207.USD","LU1226287875.USD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662695887","title":"再鼎医药：上半年净亏损1.02亿美元 同比扩大14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662695887","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662695887?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:22","pubTimestamp":1787707320,"startTime":"0","endTime":"0","summary":"8月26日，再鼎医药（09688/ZLAB）发布2026年中期业绩，公司产品收入净额为2.01亿美元，同比下降6%，主要由于则乐的收入下降（受奥拉帕利仿制药入围集中采购影响）及卫伟迦的收入下降（与国家医保目录续约相关的价格调整）。这些下降部分被鼎优乐的销售额增长（受益于强劲的患者需求和医院覆盖范围的持续扩大）及纽再乐的销售额增长所抵销。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854197972.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854197972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4526","BK4531","BK4139","BK1574","BK4548","BK4588","ZLAB","LU2488822045.USD","09688","BK4585","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662765771","title":"再鼎医药（09688）中期亏损净额同比增长14.22% 产品收入净额减少6.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662765771","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662765771?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:01","pubTimestamp":1787706074,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药（09688）公布截至2026年6月30日止六个月的中期业绩，亏损净额1.02亿美元，同比增长14.22%，主要由于许可费的增加。每股基本亏损0.09美元。董事会未建议就2025年及2026年上半年派发任何中期股息。期内，实现总营收2.06亿美元，同比减少4.87%。其中，产品收入净额为2.01亿美元，同比减少6.25%，主要由于则乐的收入下降（由于奥拉帕利仿制药入围集中采购导致医院用药模式发生改变）以及卫伟迦的收入下降（主要是由于与国家医保目录续约相关的价格调整）。期内研发开支增加14%至1.27亿美元，主要由于公司的许可和合作协议项下许可费的增加。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MTU2NzYxOTI1Mjg5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MTU2NzYxOTI1Mjg5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989411","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","BK1574","BK1588","BK4526","BK4548","LU2488822045.USD","BK4588","ZLAB","BK4585","BK4139","BK4531","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662768260","title":"再鼎医药(09688.HK)发布中期业绩 亏损净额1.02亿美元 研发开支同比增加14%至1.27亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662768260","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662768260?lang=zh_cn&edition=full","pubTime":"2026-08-26 07:30","pubTimestamp":1787700633,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2488822045.USD","BK1161","BK1574","BK1588","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192639872","title":"再鼎医药（09688）2026年上半年净亏损扩大至1.02亿美元  现金储备7.09亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192639872","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192639872?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:31","pubTimestamp":1787697088,"startTime":"0","endTime":"0","summary":"8月26日，再鼎医药有限公司公布截至2026年6月30日止六个月的未审计中期业绩。期内，公司实现总收入2.06亿美元，同比减少5%。其中，产品收入净额为2.01亿美元，较2025年同期的2.15亿美元下降6%，主要因则乐收入减少及卫伟迦收入下滑，部分被鼎优乐和纽再乐销售增长所抵销。受研发投入增加等因素影响，公司净亏损由8,916.5万美元扩大至1.02亿美元，同比增幅14%。基本及摊薄每股普通股亏损0.09美元，高于上年同期的0.08美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662781278","title":"【券商聚焦】国泰海通维持再鼎医药（09688）增持 指增长动能切换至新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2662781278","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662781278?lang=zh_cn&edition=full","pubTime":"2026-08-25 15:15","pubTimestamp":1787642144,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国泰海通证券发布研报指，再鼎医药 产品收入边际改善，增长动能切换至新药，核心关注Zoci注册临床推进及ZL-1503的FIH数据。2026年上半年公司总收入2.06亿美元，同比下降5%；产品收入净额2.01亿美元，同比下降6%。2026年上半年研发费用1.27亿美元，主因许可及合作协议授权费增加；销售及管理费用1.38亿美元（+3%），基本持平。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989297","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK0028","BK0184","BK0276","BK1588","BK1574","BK4585","KCE","BK4531","BK4588","BK0012","BK1161","LU2488822045.USD","09688","BK0188","601211","BK1564","BK0201","02611","ZLAB","BK0183","BK1147","BK4526","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661244437","title":"【券商聚焦】交银国际：中国内地mRNA疫苗产业整体低估严重","url":"https://stock-news.laohu8.com/highlight/detail?id=2661244437","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661244437?lang=zh_cn&edition=full","pubTime":"2026-08-24 09:18","pubTimestamp":1787534313,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，Moderna与默沙东共同宣布，intismeran联合K药辅助治疗IIB-IV期黑色素瘤的III期INTerpath-001研究达主要终点 。该机构认为，中国内地mRNA疫苗企业正处于全球公共卫生事件后的低谷期，产业整体低估严重，但海外可比产品的研发成功和适应症领域的拓展有望推动投资情绪和估值修复。此外，康希诺、智飞生物/沃森生物/康华生物等布局mRNA技术、处于估值底部的疫苗企业也值得持续关注。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989096","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","BK1191","LU0043850808.USD","LU0244354667.USD","09688","LU0348767384.USD","LU1226287792.SGD","02269","LU0588546209.SGD","LU0516422366.SGD","01801","01877","09926","LU0348766576.USD","06160","BK1576","LU1960683339.HKD","BK1588","LU1242518931.SGD","BK1147","LU0228659784.USD","LU0320764599.SGD","LU1303224171.USD","SG9999002562.SGD","MRNY","LU0067412154.USD","BK1589","LU0307460666.USD","LU0561508036.HKD","KURE","02142","02616","LU0516423174.USD","LU0828237510.HKD","MRNX","06185","LU2488822045.USD","LU1008478684.HKD","LU0359201612.USD","09995","LU2097828557.USD","01093","LU0880133367.SGD","KCE","03329","LU1688375341.USD","LU0417516571.SGD","LU1794554557.SGD","LU0181495838.USD","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183692819","title":"再鼎医药：RTW Investments, LP增持美股","url":"https://stock-news.laohu8.com/highlight/detail?id=1183692819","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183692819?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:13","pubTimestamp":1787303584,"startTime":"0","endTime":"0","summary":"RTW Investments, LP于2026年8月20日以每股均价26美元买入再鼎医药股份1230.72万股，涉资约3.20亿美元。RTW Investments, LP此次增持前持有再鼎医药好仓8158.01万股，占比7.17%；增持后持股量为9388.74万股，好仓比例升至8.25%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.1087},{"period":"1month","weight":0.013},{"period":"3month","weight":0.4241},{"period":"6month","weight":0.3126},{"period":"1year","weight":-0.237},{"period":"ytd","weight":0.3751}],"compareEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":-0.0272},{"period":"3month","weight":0.0096},{"period":"6month","weight":-0.0201},{"period":"1year","weight":-0.0475},{"period":"ytd","weight":-0.0264}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.017355},{"month":2,"riseRate":0.666667,"avgChangeRate":0.068855},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.098942},{"month":4,"riseRate":0.666667,"avgChangeRate":0.061043},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.046017},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004904},{"month":7,"riseRate":0.666667,"avgChangeRate":0.052949},{"month":8,"riseRate":0.666667,"avgChangeRate":0.046005},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.053818},{"month":10,"riseRate":0.5,"avgChangeRate":-0.051338},{"month":11,"riseRate":0.5,"avgChangeRate":0.047251},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.024481}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}